PDF 1.0 MB
BD investing $1.2 billion into manufacturing of prefillable injection systems
BD has plans to invest
approximately $1.2 billion over a 4-year period. The
investment will fund capacity
expansion, new product innovations,
enhancements and business
continuity improvements across its
existing network, all designed to
maximize supply and reduce risks for
pharmaceutical companies that rely
on ready-to-fill syringes for their
injectable drugs - including
complex biologics, vaccines and
small molecules -. A new manufacturing facility in Europe is expected to be operational by the end of 2023.
More information available in our datasheet.